Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-18-320973
Filing Date
2018-11-07
Accepted
2018-11-07 16:32:05
Documents
48
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d635582d10q.htm 10-Q 374175
2 EX-31.1 d635582dex311.htm EX-31.1 6375
3 EX-31.2 d635582dex312.htm EX-31.2 6394
4 EX-32 d635582dex32.htm EX-32 5076
  Complete submission text file 0001193125-18-320973.txt   3005525

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT itci-20180930.xml EX-101.INS 586540
6 XBRL TAXONOMY EXTENSION SCHEMA itci-20180930.xsd EX-101.SCH 31963
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE itci-20180930_cal.xml EX-101.CAL 41779
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE itci-20180930_def.xml EX-101.DEF 131014
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20180930_lab.xml EX-101.LAB 314499
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20180930_pre.xml EX-101.PRE 227406
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36274 | Film No.: 181166784
SIC: 2834 Pharmaceutical Preparations